observed in patients who recovered a normal LVEF, compared to those with persistent cardiac dysfunction, even if asymptomatic, thus underscoring the inadequacy of a symptom-guided approach. Lack of cardio-oncology consultation may represent a missed opportunity for early diagnosis and intervention.

*Carol Chen-Scarabelli, PhD  
Tiziano M. Scarabelli, MD, PhD  
*Department of Veterans Affairs Healthcare System  
Richmond VA Medical Center  
Division of Cardiology  
1201 Broad Rock Boulevard  
Richmond, Virginia 23249  
E-mail: chenscarabelli@hotmail.com  

Published by Elsevier on behalf of the American College of Cardiology Foundation

Please note: The authors have reported that they have no relationships relevant to the contents of this paper to disclose.

REFERENCES


The Need for Cardiovascular Risk Factor Prevention in Cardio-Oncology

We read with interest the elegant paper by Jones et al. (1), investigating progression from stage A to stage B heart failure (HF) after potentially cardiotoxic chemotherapies.

Given the known influence of cardiovascular risk factors (CVRF) on the development of cardiotoxicity (2,3), the absence of a relationship between the number of CVRF and transition to stage B HF is surprising, even considering the small sample size. A possible explanation may be that CVRF were well controlled, and thus, their detrimental effect was blunted. This may be even more so keeping in mind that the association of CVRF with cardiotoxicity has mainly been identified by retrospective analyses of cohorts in whom management of CVRF might not have been as prompt as in a prospective cardio-oncology study such as that by Jones et al. (1).

However, in the cohort of the study by Jones et al. (1), the prevalence of CVRF was substantial. This also has been our experience. For instance, among 604 unselected patients visited at our cardio-oncology outpatient clinic prior starting chemotherapy in 2016, 300 subjects (49.7%) had hypertension. Notably, 69 of them did not have blood pressure values on target. Moreover, of the remaining 304 subjects, 40 received a new diagnosis of hypertension.

We believe findings from these different experiences require considerable attention. The most robust predictor of HF in patients with cancer is still an anthracycline-based regimen (1). In the study by Jones et al. (1), 67.2% of patients were ≥60 years of age, and thus had a long-life expectancy. Because anthracycline cardiotoxicity may occur late after exposure (4), cardiovascular surveillance must remain a priority, with a structured follow-up. In this context, prevention of CVRF should become an essential part of oncological assessment prior to chemotherapy.

Giacomo Tini, MD  
Matteo Sarocchi, MD  
Pietro Ameri, MD, PhD  
Eleonora Arboscello, MD  
*Paolo Spallarossa, MD  
*Clinic of Cardiovascular Diseases  
IRCCS San Martino Policlinic Hospital  
Largo Rosanna Benzi 10  
16132 Genova  
Italy  
E-mail: paolo.spallarossa@unige.it  
https://doi.org/10.1016/j.jchf.2019.01.002

© 2019 by the American College of Cardiology Foundation. Published by Elsevier.

Please note: The authors have reported that they have no relationships relevant to the contents of this paper to disclose.

REFERENCES


Novel Risk Stratification for Chemotherapy-Induced Heart Failure

We took an interest in the study by Jones et al. (1) initiating potentially cardiotoxic chemotherapy and the frequency of transitioning from stage A to more advanced heart failure (HF) stages. This study was conducted in individuals scheduled to undergo chemotherapy with potential cardiotoxicity to assess the change in HF stage from baseline to 3 to 6 and 12 to 24 months after treatment (1). Risk factors associated with cardiotoxicity have been the focus of attention, providing new methods for the accurate treatment of chemotherapy-induced HF.

Firstly, this study continuously recruited 144 patients and prospectively assessed the risk factors affecting HF stages, including the rate of progression to more advanced HF after chemotherapy. The authors found that smoking was a risk factor for the transition to stage B at 12 to 24 months and the combination of anthracycline and trastuzumab resulted in the transition from stage A to stage B at 6 months (1). A retrospective study of 16,456 patients also found that the risk of cardiotoxicity increased in patients aged ≥65 years old with pre-existing hypertension who were treated with trastuzumab and anthracyclines (2). However, diagnostic sensitivity and predictive power to detect chemotherapy-induced HF were expected to be proven further through clinical research. Secondly, this study (1) did not find that cardioprotective drugs had an alleviating effect on chemotherapy-induced HF. At 3 months, there was no statistical difference between the application of angiotensin-converting enzyme inhibitors in stage A and stage B, which were 26.7% and 25.9%, respectively. However, a recent study found that early initiation of standard HF medical treatment might lead to left ventricular (LV) function recovery in anthracycline-induced cardiotoxicity (AIC) (3). Unfortunately, there is not enough clinical evidence in this study to indicate that standard HF medications are recommended for patients with LV dysfunction or at high risk of AIC (3). In addition, the pre-treatment data from the cardioprotective medication group and the noncardioprotective medication group were not elaborated in the study, which may lead to statistical bias. Finally, unfortunately, this study did not perform related research on the biomarkers produced by cardiovascular stress which can be used to predict LV systolic dysfunction, thereby identifying some high-risk patients and actively intervening to reduce the morbidity and mortality (4). One such study suggested that 3 genomic markers significantly increased the risk for AIC, namely, ABC2 rs8187710, CYBA rs4673, and RAC2 rs13058338 (5). This will significantly improve the reliability of the results and provide a rapidly and accurately prediction of cardiovascular toxicity event in the future.

Overall, this study described the frequency of transitioning from stage A to more advanced HF stages in detail, including the timepoints and risk factors leading to HF development in patients receiving potentially cardiotoxic chemotherapy. A novel idea and research direction for studying cardiotoxicity has been given us by this study despite the small sample size. In the future, a better understanding and the early identification of the risk factors of HF in cancer patients will prevent the progression of HF induced by cardiotoxicity, and more effective treatment options for HF prevention will be determined.

Na An, MD
Xinye Li, MD
Hongcai Shang, MD, PhD
Yonghong Gao, MD, PhD
*Yanwei Xing, MD, PhD
*Guang’anmen Hospital
Chinese Academy of Chinese Medical Sciences
Department of Cardiology
Beixiange 5
Xichen District
Beijing
China
E-mail: xingyanwei12345@163.com
https://doi.org/10.1016/j.jchf.2019.01.013
© 2019 by the American College of Cardiology Foundation. Published by Elsevier.

Please note: The authors have reported that they have no relationships relevant to the contents of this paper to disclose.

REFERENCES